1 Papp-Wallace KM, Endimiani A, Taracila MA, et al. Carbapenems: Past, present, and future. Antimicrob Agents Chemother 2011;55:4943–60. doi:10.1128/AAC.00296-11
2 Hawkey PM, Livermore DM. Carbapenem antibiotics for serious infections. BMJ 2012;344:1–7. doi:10.1136/bmj.e3236
3 Li Y, Sun Q-L, Shen Y, et al. Rapid Increase in Prevalence of Carbapenem-Resistant Enterobacteriaceae (CRE) and Emergence of Colistin Resistance Gene mcr-1 in CRE in a Hospital in Henan, China. J Clin Microbiol 2018;56:e01932-17. doi:10.1128/JCM.01932-17
4 Thaden JT, Lewis SS, Hazen KC, et al. Rising Rates of Carbapenem-Resistant Enterobacteriaceae in Community Hospitals: A Mixed-Methods Review of Epidemiology and Microbiology Practices in a Network of Community Hospitals in the Southeastern United States. Infect Control Hosp Epidemiol 2014;35:978–83. doi:10.1086/677157
5 Wan PJ, Jae LS, Hyungmin L. Status of carbapenemase-producing enterobacteriaceae incidences in Korea, 2015-2016. Public Heal Wkly Report, Korea Dis Control Prev Agency 2017;10:1243–7.
6 Martin A, Fahrbach K, Zhao Q, et al. Association between carbapenem resistance and mortality among adult, hospitalized patients with serious infections due to enterobacteriaceae: Results of a systematic literature review and meta-analysis. Open Forum Infect Dis 2018;5:1–9. doi:10.1093/ofid/ofy150
7 Matthew E. Falagas, Giannoula S. Tansarli, Drosos E. Karageorgopoulos, et al. Deaths Attributable to Carbapenem-Resistant Enterobacteriaceae Infections. Emerg Infect Dis 2014;20:1170–5.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4073868/pdf/12-1004.pdf
8 Queenan AM, Bush K. Carbapenemases: The versatile β-lactamases. Clin Microbiol Rev 2007;20:440–58. doi:10.1128/CMR.00001-07
9 Pitout JDD. Multiresistant Enterobacteriaceae: new threat of an old problem. Expert Rev Anti Infect Ther 2008;6:657–69. doi:10.1586/14787210.6.5.657
10 Nordmann P. Carbapenemase-producing Enterobacteriaceae: overview of a major public health challenge. Med Mal Infect 2014;44:51–6. doi:10.1016/j.medmal.2013.11.007
11 Korea Disease Control and Prevention Agency. Guidelines for control of patients with Carbapenemase producing Carbapenem-Resistant Enterobacteriaceae. 2020.
12 Jamal AJ, Faheem A, Farooqi L, et al. Household Transmission of Carbapenemase-Producing Enterobacterales (CPE) in Ontario, Canada. Clin Infect Dis Published Online First: 1 September 2020. doi:10.1093/cid/ciaa1295
13 Park JW, Kwak SH, Jung J, et al. The rate of acquisition of carbapenemase-producing Enterobacteriaceae among close contact patients depending on carbapenemase enzymes. Infect Chemother 2020;52:39–47. doi:10.3947/ic.2020.52.1.39
14 Wayne PA. Clinical and Laboratory Standards Institute Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically Standard,, Approval CDM-A.; Clin Lab Stand Inst 2018;:91.
15 EUCAST. Testing Breakpoint tables for interpretation of MICs and zone diameters. 2020. https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_10.0_Breakpoint_Tables.pdf
16 Lusignani LS, Presterl E, Zatorska B, et al. Infection control and risk factors for acquisition of carbapenemase-producing enterobacteriaceae . A 5 year ( 2011 – 2016 ) case-control study. Antimicrob Resist Infect Control 2020;9:1–10.
17 Falagas ME, Rafailidis PI, Kofteridis D, et al. Risk factors of carbapenem-resistant Klebsiella pneumoniae infections : a matched case – control study. 2007;:1124–30. doi:10.1093/jac/dkm356
18 Mariappan S, Sekar U, Kamalanathan A. Carbapenemase-producing Enterobacteriaceae: Risk factors for infection and impact of resistance on outcomes. Int J Appl basic Med Res 2017;7:32–9. doi:10.4103/2229-516X.198520
19 Nicolas-Chanoine M-H, Vigan M, Laouénan C, et al. Risk factors for carbapenem-resistant Enterobacteriaceae infections: a French case-control-control study. Eur J Clin Microbiol Infect Dis 2019;38:383–93. doi:10.1007/s10096-018-3438-9
20 Mathers AJ, Vegesana K, German-Mesner I, et al. Risk factors for Klebsiella pneumoniae carbapenemase (KPC) gene acquisition and clinical outcomes across multiple bacterial species. J Hosp Infect 2020;104:456–68. doi:10.1016/j.jhin.2020.01.005
21 Mataseje LF, Abdesselam K, Vachon J, et al. Results from the Canadian Nosocomial infection surveillance program on Carbapenemase-producing Enterobacteriaceae, 2010 to 2014. Antimicrob Agents Chemother 2016;60:6787–94. doi:10.1128/AAC.01359-16
22 Legeay C, Thépot-Seegers V, Pailhoriès H, et al. Is cohorting the only solution to control carbapenemase-producing Enterobacteriaceae outbreaks? A single-centre experience. J Hosp Infect 2018;99:390–5. doi:10.1016/j.jhin.2018.02.003
23 Mollema FPN, Richardus JH, Behrendt M, et al. Transmission of methicillin-resistant Staphylococcus aureus to household contacts. J Clin Microbiol 2010;48:202–7. doi:10.1128/JCM.01499-09
24 Clarivet B, Grau D, Jumas-Bilak E, et al. Persisting transmission of carbapenemase-producing Klebsiella pneumoniae due to an environmental reservoir in a university hospital, France, 2012 to 2014. Eurosurveillance 2016;21. doi:10.2807/1560-7917.ES.2016.21.17.30213
25 Smismans A, Ho E, Daniels D, et al. New environmental reservoir of CPE in hospitals. Lancet Infect Dis 2019;19:580–1. doi:10.1016/S1473-3099(19)30230-0
26 De Geyter D, Blommaert L, Verbraeken N, et al. The sink as a potential source of transmission of carbapenemase-producing Enterobacteriaceae in the intensive care unit. Antimicrob Resist Infect Control 2017;6:1–6. doi:10.1186/s13756-017-0182-3